Portfolio of 15 generic and over-the-counter (OTC) medicines from Sandoz division addresses urgent unmet needs of low- and lower-middle-income countries to treat patients with COVID-19 symptoms
Portfolio will be sold at zero-profit to governments in up to 791 eligible countries during the pandemic and until a vaccine or curative treatment is available
Early access to treatment for managing COVID-19 symptoms is critical to preventing healthcare system overload
Cancer Access Partnership is expected to result in a 59 percent savings on procured cancer medicines
Press Release
June 29, 2020 /3BL Media/ - The American Cancer Society (ACS) and the Clinton Health Access Initiative (CHAI) today announced agreements with pharmaceutical companies Pfizer, Novartis, and Mylan to expand access to 20 lifesaving cancer treatments in 26 countries in sub-Saharan Africa and Asia. Purchasers are expected to save an average of 59 percent for medicines procured through the agreements.
Maximizing Technology, Time & Teamwork for Critical Impact, Now
Blog
No question, the last eight weeks have been tough on everyone. As a pharma company, Novartis felt a duty to respond and call to be part of the solution. The Novartis purpose is to re-imagine medicine to improve and extend people's lives. The Novartis' purpose statement is aligned with four key areas: holding themselves to the highest ethical standards, being part of the solution on pricing and access to medicines, helping tackle global health challenges, and being a responsible citizen.
May 6, 2020 /3BL Media/ - Fondation Botnar and Novartis will support research capacity development in sub-Saharan Africa within the framework of EDCTP’s 2020 Career Development Fellowships. Collectively, the two organisations will contribute up to a maximum of €2.25 million to the initial EDCTP call budget of €1.5 million. Their investments will support successful proposals to conduct research on child and adolescent health with a focus on the interaction between poverty-related infectious diseases and non-communicable diseases.
The impact of the Coronavirus (COVID-19) outbreak continues to disrupt our society as we know it, for many becoming a matter of life or death. While there is ongoing research & development work to identify solutions to address the pandemic, managed or expanded access to medicines is now more critical than ever to help address some of the urgent patient needs at various COVID-19 epicenters.
Partnership with NJPCA, which represents 23 community health centers in NJ, funded 5 telehealth pilots; programs serving as role models for centers across state
The Grant enabled NJ community health centers to quickly implement telehealth to maintain continuity of care for underserved communities, especially critical during the current COVID-19 pandemic
Novartis US Foundation supports programs to reimagine healthcare through use of digital tools to reduce barriers to care
Press Release
Partnership with NJPCA, which represents 23 community health centers in NJ, funded 5 telehealth pilots; programs serving as role models for centers across state
The Grant enabled NJ community health centers to quickly implement telehealth to maintain continuity of care for underserved communities, especially critical during the current COVID-19 pandemic
Novartis US Foundation supports programs to reimagine healthcare through use of digital tools to reduce barriers to care
Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease
Trial is designed and implemented quickly to address the need for science-based investigation following early preclinical and clinical evidence1,2,3 that hydroxychloroquine may help hospitalized patients with COVID-19 disease
Company will also make its hydroxychloroquine intellectual property available to support broad access if medicine is approved for COVID-19
Study complements Novartis commitment to donate up to 130 million doses of hydroxychloroquine globally to support the COVID-19 pandemic response
Novartis has a broad COVID-19 research and development commitment, including multiple large sponsored and investigator initiated clinical trials of its medicines
Press Release
Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease
Trial is designed and implemented quickly to address the need for science-based investigation following early preclinical and clinical evidence1,2,3 that hydroxychloroquine may help hospitalized patients with COVID-19 disease
Company will also make its hydroxychloroquine intellectual property available to support broad access if medicine is approved for COVID-19
Study complements Novartis commitment to donate up to 130 million doses of hydroxychloroquine globally to support the COVID-19 pandemic response
Novartis has a broad COVID-19 research and development commitment, including multiple large sponsored and investigator initiated clinical trials of its medicines
For the first time in history, the global health community is preparing to celebrate World Chagas Disease Day. Novartis is joining the global movement to raise visibility and awareness of patients with Chagas disease1.
